AIM ImmunoTech Inc. (NYSE American: AIM) announced it entered into definitive agreements for a registered direct offering and concurrent private placement that will generate approximately $2.65 million in gross proceeds before deducting placement agent commissions and other offering expenses.

The offering is expected to close on or about June 10, 2026, subject to customary closing conditions. Ladenburg Thalmann & Co. Inc. serves as the exclusive placement agent for the transaction.

Under the terms, AIM ImmunoTech will issue 2,554,119 shares of common stock at $0.5189 per share in the registered direct offering. The concurrent private placement will include an equal number of unregistered common stock shares and Class J warrants to purchase up to 10,216,476 shares of common stock.

The Class J warrants carry an exercise price of $0.5189 per share, require stockholder approval for exercise, and will expire five years from the initial exercise date.

The company stated it intends to use net proceeds for manufacturing clinical drug supply, current clinical trial activities, planned Phase 3 clinical trial activities, and working capital purposes.

The registered shares are being offered through a prospectus supplement under the company's shelf registration statement on Form S-3, which the Securities and Exchange Commission declared effective on July 3, 2025. The unregistered shares and warrants will be issued through a private placement under exemptions from Securities Act registration requirements.

AIM ImmunoTech focuses on developing therapeutics for cancers, immune disorders and viral diseases. The company's lead product candidate is Ampligen, described as a first-in-class investigational drug and TLR3 agonist immuno-modulator in clinical trials.